https://doi.org/10.4081/itjm.2024.1666
Clostridioides difficile infection in hospital and community settings: summary document of a multidisciplinary group
Published: 7 February 2024
Abstract Views: 1869
PDF: 441
HTML: 46
HTML: 46
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Clostridioides difficile infection (CDI) affects the majority of hospital wards. In the context of a Continuing Medical Education Field Training course, a multidisciplinary group of expert healthcare professionals addressed the issue of CDI, producing a summary document to be submitted to the scientific community. The expert group was composed of healthcare professionals with an internal medicine background (Internal Medicine, Infectious Diseases, Nephrology, Gastroenterology, Geriatrics) with the contribution of a Microbiologist for the laboratory diagnostic aspects. During the draft of the document, various aspects of the problem were evaluated and developed.
Downloads
Download data is not yet available.
PlumX Metrics
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
Citations
Van Dorp SM, Kinross P, Gastmeier P, et al. European Clostridium difficile Infection Surveillance Network (ECDIS-Net) on behalf of all participants. Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013. Euro Surveill 2016; 21.
DOI: https://doi.org/10.2807/1560-7917.ES.2016.21.29.30293
Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, pointprevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014;14:1208-19.
DOI: https://doi.org/10.1016/S1473-3099(14)70991-0
Roncarati G, Dallolio L, Leoni E, et al. Surveillance of Clostridium difficile Infections: results from a six-year retrospective study in nine hospitals of a north italian local health authority. Int J Environ Res Public Health 2017;14:61.
DOI: https://doi.org/10.3390/ijerph14010061
Cofini V, Muselli M, Gentile A, et al. Clostridium difficile outbreak: epidemiological surveillance, infection prevention and control. J Prev Med Hyg 2021;62:E514.
Girinathan BP, Braun S, Sirigireddy AR, et al. Correction: Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo. PLoS ONE 2016;11:e0160107.
DOI: https://doi.org/10.1371/journal.pone.0160107
Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124.
Dubberek ER, Burnham CAD. Diagnosis of Clostridium difficile Infection. Treat the patient, Not the Test. JAMA Intern Med 2015;175:1801.
DOI: https://doi.org/10.1001/jamainternmed.2015.4607
Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015;313:398.
DOI: https://doi.org/10.1001/jama.2014.17103
Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021;73:e1029.
DOI: https://doi.org/10.1093/cid/ciab549
van Prehn J, Reigadas E, Vogelzang EH, et al. Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021;27:S1.
DOI: https://doi.org/10.1016/j.cmi.2021.09.038
Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: prevention, diagnosis, and treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124.
DOI: https://doi.org/10.14309/ajg.0000000000001278
Clostridioides difficile infection: antimicrobial prescribing. NICE guideline. 23 July 2021. Available from: https://www.nice.org.uk/guidance/ng199/chapter/Recommendations#choice-of-antibiotic
Bishop EJ, Tiruvoipati R. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. J Antimicrob Chemother 2022;78:21.
DOI: https://doi.org/10.1093/jac/dkac404
van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect 2022;28:321.
DOI: https://doi.org/10.1016/j.cmi.2021.09.026
Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019;38:1211.
DOI: https://doi.org/10.1007/s10096-019-03539-6
Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017;3:CD004610.
DOI: https://doi.org/10.1002/14651858.CD004610.pub5
Sirbu BD, Soriano MM, Manzo C, et al. Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection. Clin Infect Dis 2017;65:1396.
DOI: https://doi.org/10.1093/cid/cix529
Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422.
DOI: https://doi.org/10.1056/NEJMoa0910812
Wilcox MH, Gerding DN, Poxton IR, et al. MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017;376:305.
DOI: https://doi.org/10.1056/NEJMoa1602615
Hyte ML, Arphai LJ, Vaughn CJ, Durham SH. The role of Bezlotoxumab for the prevention of recurrent Clostridioides difficile Infections: a review of the current literature and paradigm shift after 2021. Antibiotics (Basel) 2022;11:1211.
DOI: https://doi.org/10.3390/antibiotics11091211
McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1.
DOI: https://doi.org/10.1093/cid/cix1085
Feuerstadt P, Aroniadis OC, Svedlund FL, et al. Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Dig Dis Sci 2022;67:2763.
DOI: https://doi.org/10.1007/s10620-021-07141-9
Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019;68:2111.
DOI: https://doi.org/10.1136/gutjnl-2019-319548
Gonzales Luna AJ, Carlson TJ, Garey KW. Emerging Options for the Prevention and Management of Clostridioides difficile Infection. Drugs 2023;83:105.
DOI: https://doi.org/10.1007/s40265-022-01832-x
Nanwa N, Kendzerska T, Krahn M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol 2015;110:511.
DOI: https://doi.org/10.1038/ajg.2015.48
McDaniel LF, White MN, Obi EN, et al. Clinical and economic outcomes after implementation of a fidaxomicin treatment optimization and access pathway at a US hospital system. Infect Dis Ther 2023;12:95.
DOI: https://doi.org/10.1007/s40121-022-00665-1
Whitney L, Nesnas J, Planche T. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection. Antibiotics (Basel) 2023;12:106.
DOI: https://doi.org/10.3390/antibiotics12010106
Petrosillo N, Ravasio R. Il costo ospedaliero di trattamento di un episodio di infezione da Clostridium difficile in Italia. GRHTA 2017;4:77.
DOI: https://doi.org/10.33393/grhta.2017.380
Patroni A, Bertoni C. Raccomandazioni per la prevenzione e il controllo delle infezioni da Clostridium difficile. GIMPIOS 2022;12:4.
How to Cite
Danise, A., Furfaro, F., Gattuso, G., Liberato, N. L., Mandelli, C., Mazzola, G., & Osnaghi, B. (2024). <i>Clostridioides difficile</i> infection in hospital and community settings: summary document of a multidisciplinary group. Italian Journal of Medicine, 18(1). https://doi.org/10.4081/itjm.2024.1666
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.